Levetiracetam

규격

102767-28-2CAS 번호

600-348-9EC 번호

(2S)-2-(2-oxopyrrolidin-1-yl)butanamideIUPAC 명칭

C8H14N2O2화학식

170.21 g/mol분자량

Levetiracetam; 102767-28-2; Keppra; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; Keppra XR; Spritam; UCB-L 059; ucb L059; matever; Levetiracetame; Levetiracetamum; UCB-L059; Elepsia; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; Levetiracetam sun; E Keppra; Elepsia XR; Levetiracetam teva; Levetiracetam accord; Levetiracetam actavis; Levetiracetam hospira; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; UCB-22059; UCB 22059; NSC-760119; Levetiracetam In Sodium Chloride; AGB-101; N03AX14; 44YRR34555; LEVETIRACETAM RATIOPHARM; CHEBI:6437; DTXSID9023207; LEVETIRACETAM ACTAVIS GROUP; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (S)-; Desitrend; Roweepra; Levetiracetam ER; Etiracetam, R; Etiracetam, S; Levetiracetam oral; Etiracetam, S-; R-isomer Etiracetam; S-isomer Etiracetam; LEVERTIRACETAM; Levetiracetam Injection; RefChem:5943; ucb-L060; UcbL060; Levetiracetam Levetiracetam; Levetiracetam Extended-release; DTXCID503207; ELEPSIA XR 1000 MG; ELEPSIA XR 1500 MG; UCB6474; alpha ethyl 2 oxo 1 Pyrrolidineacetamide; 1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-,(S)-; 600-348-9; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; SIB-S1; MFCD03265610; Levetiracetam [INN]; Levetiracetamum [INN-Latin]; Levroxa; (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide; Leviteracetam; Levipil; Torleva; (S)-Levetiracetam; SMR000466303; Keppra (TN); Levesam 500; Etiracetam levo-isomer; SR-01000759400; s1356; UNII-44YRR34555; HSDB 7528; Levetiracetam CRS; 1-Pyrrolidineacetamide, a-ethyl-2-oxo-; a-Ethyl-2-oxo-1-pyrrolidineacetamide; Etiracetam; UCB 6474; (2RS)-2-(2-Oxopyrrolidin-1-yl)butanamide; Levetiracetam [USAN:USP:INN:BAN]; E keppra (TN); (S)-2-(2-Oxo-1-pyrrolidinyl)butyramide; L-059; LEVETIRACETAM [MI]; LEVETIRACETAM [JAN]; CHEMBL1286; LEVETIRACETAM [HSDB]; LEVETIRACETAM [USAN]; LEVETIRACETAM [VANDF]; MLS000759403; MLS001424069; MLS006010215; BIDD:GT0242; LEVETIRACETAM [MART.]; SCHEMBL118843; LEVETIRACETAM [USP-RS]; LEVETIRACETAM [WHO-DD]; GTPL6826; orb1310850; orb3141186; SCHEMBL6650425; LEVETIRACETAM [EMA EPAR]; Levetiracetam (JP19/USP/INN); HPHUVLMMVZITSG-LURJTMIESA-N; Levetiracetam - Bio-X trade mark; Levetiracetam, >=98% (HPLC); Levetiracetam, analytical standard; GLXC-03020; HMS2051D07; HMS2089L20; HMS2235I18; HMS3262H11; HMS3713P16; HMS3884O11; Levetiracetam, 1mg/ml in Methanol; Pharmakon1600-01502265; LEVETIRACETAM [EP IMPURITY]; LEVETIRACETAM [ORANGE BOOK]; ALBB-027275; HY-B0106; MSK10598; LEVETIRACETAM [EP MONOGRAPH]; LEVETIRACETAM [USP IMPURITY]; Tox21_500835; BDBM50422542; EBC-06279; LEVETIRACETAM [USP MONOGRAPH]; NSC760119; STL388027; Levetiracetam 1.0 mg/ml in Methanol; AKOS015841981; AC-1479; CCG-100928; CS-1854; DB01202; FL24879; KS-1176; LP00835; NC00178; NSC 760119; SDCCGSBI-0633760.P001; NCGC00186028-01; NCGC00186028-12; NCGC00186028-13; NCGC00261520-01; (S)-2-(2-oxopyrrolidin-1-yl)butyramide; BL164623; (s)-2-(2-oxopyrrolidin-1-yl) butyramide; (a-S)-a-Ethyl-2-oxo-1-pyrrolidineacetamide; L0234; L1784; SW197558-3; C07841; D00709; EN300-244575; AB00639945-06; AB00639945_07; AB00639945_08; F079444; (S)-2-(2-OXO-PYRROLIDIN-1-YL)-BUTYRAMIDE; 1-Pyrrolidineacetamide, |A-ethyl-2-oxo-, (|AS)-; SR-01000759400-4; SR-01000759400-5; BRD-K49404994-001-09-1; BRD-K49404994-001-10-9; BRD-K49404994-001-11-7; Z1255435426; (-)-(S)-.ALPHA.-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE; 1-Pyrrolidineacetamide, .alpha.-ethyl-2-oxo-, (.alpha.S)-; Levetiracetam Working Standard (Secondary Reference Standard); Levetiracetam, European Pharmacopoeia (EP) Reference Standard; Levetiracetam, United States Pharmacopeia (USP) Reference Standard; (-)-(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide (2S)-2-(2-Oxo-pyrrolidin-1-yl)butanamide; Levitiracetam, Pharmaceutical Secondary Standard; Certified Reference Material; Livetiracetam; ケプラ동의어